Evidence map›Paper›PMID 27133816›Full record

ArticleLeukemia2016

Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant.

Y Wang, H-X Wang, Y-R Lai, Z-M Sun, D-P Wu, M Jiang, D-H Liu, K-L Xu, Q-F Liu, L Liu and 6 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Conditioning Regimen Options.Advances in experimental medicine and biology · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Y WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
H-X WangAir Force General Hospital, PLA, Beijing, China.
Y-R LaiDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Z-M SunAnhui Provincial Hospital, Hefei, Anhui, China.
D-P WuThe first affiliated hospital of Soochow University, Suzhou, Jiangsu, China.
M JiangDepartment of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Wulumuqi, Xinjiang, China.
D-H LiuPLA General Hospital, Beijing, China.
K-L XuThe Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China.
Q-F LiuNanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
L LiuThe first Affiliated Hospital of Chongqing Medical University, Chongqing, China.
J-B WangAero Center Space Hospital, Beijing, China.
F GaoThe Affiliated Hospital of North China University Science and Technology, Tangshan, Hebei, China.
J Ou-YangNanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
S-J GaoThe First Affiliated Hospital of Jilin University, Changchun, Jilin, China.
L-P XuPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
X-J HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Encouraging results from a small sample of patients with myelodysplastic syndrome (MDS) undergoing haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) must be extended. Furthermore, an algorithm derived from a comparison of the outcomes of HID and identical-sibling donor (ISD) HSCT must be established. Therefore, the outcomes of 454 MDS patients who underwent HSCT from HIDs (n=226) or ISDs (n=228) between 2003 and 2013 that were reported to the Chinese Bone Marrow Transplantation Registry were analyzed. Among the 3/6 HID (n=136), 4-5/6 HID (n=90) and ISD patient groups, the 4-year adjusted cumulative incidences of non-relapse mortality were 34, 29 and 16%, respectively (overall P=0.004), and of relapse were 6, 7 and 10%, respectively (overall P=0.36). The 4-year adjusted probabilities of overall survival were 58, 63 and 73%, respectively (overall P=0.07), and of relapse-free-survival were 58, 63 and 71%, respectively (overall P=0.14); pairwise comparison showed that the difference was only statistically significant in the 3/6 HID vs ISD pair. The data suggest that ISDs remain the best donor source for MDS patients while HIDs (perhaps 4-5/6 HID in particular) could be a valid alternative when an ISD is not available; human leukocyte antigen disparity had no effect on survival among the HID patients.

Indexed as

HaplotypesSiblingsTissue DonorsAdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleHematopoietic Stem Cell TransplantationHistocompatibilityHLA AntigensHumansMaleMiddle AgedMyelodysplastic SyndromesHLA Antigens

Identifiers

PMID27133816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.